Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged >= 6 years

Objective Montelukast is a leukotriene receptor antagonist administered ora lly once daily for treatment of chronic asthma in adults and children. A co mprehensive analysis of safety data from double-blind, randomized, placebo- controlled trials with montelukast has not been previously reported. Patients and methods A pooled analysis of safety data from 11 multicentre, randomized, controlled montelukast Phase IIb and III trials and five long-t erm extension studies was performed. A total of 3386 adult patients (a,oed 15-85 years) and 336 paediatric patients (aged 6-14 years) were enrolled in the trials; 2031 adults received montelukast for up to 4.1 years, and 257 children received montelukast for up to 1.8 years. Summary statistics compa ring incidences of adverse events among treatment groups were calculated. Results The overall incidence of clinical and laboratory adverse events amo ng montelukast-treated patients, both adult and paediatric, was similar to that among patients receiving placebo. There were no clinically relevant di fferences in individual adverse events, including infectious upper respirat ory conditions and transaminase elevations, between montelukast and placebo groups. Discontinuations due to adverse events occurred with similar frequ encies during placebo, montelukast and inhaled beclomethasone therapy. No d ose-related adverse effects of montelukast were observed in adults treated with dosages as high as 200 mg per day (20 times the recommended dose) for 5 months. This tolerability profile montelukast observed in clinical trials has been generally reflected in the post-marketing safety experience seen to date. Conclusion These data indicate a tolerability profile for montelukast simil ar to placebo during both short-term and long-term administration, even at doses substantially higher than the recommended clinical dose of 10 mg once daily for adults and 5 mg once daily for children aged 6-14 years.